GleamWall
中文EN

SABS SAB Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%

Returns

ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$114,698
R&D expense$18.08M$16.17M$13.40M$10.73M$8.97M$7.00M$7.66M$7.65M
SG&A expense$7.82M$7.21M$6.60M$5.04M$3.71M$2.73M$3.11M$2.47M
Operating income-$25.90M-$23.38M-$20.00M-$15.77M-$12.68M-$9.73M-$10.77M-$10.01M
Interest expense—$62,000$62,745$63,462$43,292$64,000$69,565$70,876
Net income-$22.30M-$22.49M-$18.87M-$16.86M$45.45M-$10.11M-$5.20M-$11.39M
EBITDA-$25.10M-$22.58M-$19.27M-$15.03M-$11.98M-$8.93M-$10.02M-$9.24M
EPS (basic)-0.24-0.28-0.35—0.50-1.09-0.56—
EPS (diluted)-0.24-0.28-0.35—-0.21-1.09-0.56—
Weighted avg. shares (diluted)93.24M79.75M53.56M—77.86M9.29M9.29M—
Banking
Net interest income$1.61M———$612,000———
Balance sheet
Cash & equivalents$14.44M$8.27M$20.52M$10.50M$29.42M$3.69M$5.64M$8.90M
Short-term investments$89.61M$94.36M$86.87M$86.09M$81.46M$2.02M$7.21M$11.86M
Current assets$107.74M$107.94M$112.78M$101.05M$113.28M$9.31M$16.30M$23.79M
PP&E, net$15.65M$14.23M$13.81M$13.31M$13.11M$13.86M$14.61M$15.37M
Total assets$235.64M$238.21M$248.47M$172.81M$183.45M$30.13M$38.12M$44.20M
Current liabilities$14.80M$11.71M$9.85M$10.68M$10.79M$10.68M$9.65M$7.98M
Total liabilities$24.72M$23.43M$21.22M$21.32M$18.37M$18.11M$16.71M$18.23M
Shareholders' equity$210.92M$214.78M$227.25M$151.50M$165.07M$12.02M$21.41M$25.97M
Shares outstanding91.14M83.49M75.74M47.61M47.49M9.29M9.29M9.29M
Cash flow statement
Operating cash flow-$13.02M-$9.84M-$14.27M-$16.78M-$13.05M-$7.15M-$7.80M-$9.53M
Capital expenditure$1.34M$1.59M$983,257————$55,377
Free cash flow-$14.37M-$11.43M-$15.25M————-$9.59M
Investing cash flow$6.07M-$4.88M-$65.65M-$1.71M-$129.87M$5.20M$4.67M$9.33M
Financing cash flow$13.00M$2.36M$89.92M-$41,685$168.69M-$173,844-$173,985$216,961
Depreciation & amortization$800,000$800,000$730,965$741,593$700,000$800,000$756,595$764,007
Stock-based compensation$7.44M$7.25M$5.46M$3.17M$801,000$627,000$612,951$674,135

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.